AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$256.46-1.44%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · ABBV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 6.5% |
| Our one-year growth estimate | diamond | 10.3% |
Growth built into the price is above our model estimate.
The price assumes 3.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 10 industry peers · Company calendar date is not available
ABBV — debt issuance
Dated 2026-08-18
Other Events. On August 18, 2026, AbbVie Inc. (“ AbbVie ”) completed its previously announced underwritten public offering (the “ Notes Offering ”) of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “ Floating Rate Notes ”), $1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028 (the “ 2028 Notes ”), $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2030 (the “ 2030 Notes ”), $1,500,000,000 aggregate princip…
Why it matters: Successful debt issuance helps AbbVie with its capital strategy. It supports future investments.
Watch forCompletion of the $750M debt issuance announced in 2026-Q1.
Also watch forFailure to complete the planned debt issuance.
Why it matters: Approval would give a new treatment option. It would help AbbVie’s immunology portfolio.
Supportive ifFDA approves Rinvoq for severe hair loss.
Worry ifFDA denies approval or delays decision on Rinvoq.
Why it matters: Approval could expand Skyrizi's market and increase revenue potential. It shows AbbVie's pipeline strength.
Supportive ifFDA grants approval for Skyrizi for Crohn's disease treatment.
Worry ifFDA denies approval for Skyrizi for Crohn's disease treatment.
Why it matters: The acquisition could make AbbVie's immunology portfolio better. It may help bring in more money.
Supportive ifThe acquisition closes as planned in Q3 2026.
Worry ifThe acquisition may face delays or get canceled.
Why it matters: An increase in EPS guidance would signal strong operational performance and growth.
Supportive ifAbbVie raises adjusted EPS guidance for 2026 above $14.28.
Worry ifAbbVie maintains or lowers adjusted EPS guidance below $14.08.
Why it matters: New approvals for Rinvoq could grow its market. This may help revenue growth in immunology.
Supportive ifRinvoq gets more approvals in the EU for new uses. This boosts its market presence.
Worry ifRinvoq fails to secure new approvals in the EU, limiting its growth potential.
Why it matters: The acquisition could affect earnings per share. Monitoring this helps assess growth potential.
Worry ifEPS guidance drops below $13.87 because of Apogee acquisition costs.
Less concerning ifEPS guidance stays at or above $13.87 after the acquisition.
Why it matters: A change in EPS guidance could signal shifts in financial health and growth expectations.
Watch forAdjusted diluted EPS guidance is now above $14.07 for 2026.
Also watch forGuidance lowered below $13.87 for 2026.
Why it matters: Rinvoq's new approvals could boost sales. This shows how well AbbVie is expanding its portfolio.
Supportive ifRinvoq sales go over $2.5 billion in Q3 2026 after new approvals.
Worry ifRinvoq sales fall below $2.5 billion in Q3 2026 despite new approvals.
Why it matters: Good results could help ABBV-295 become a treatment for weight management.
Supportive ifPositive topline results from the next phase of the ABBV-295 study.
Worry ifBad results or safety issues may come from ongoing studies.
Why it matters: Skyrizi sales are growing. This shows strong demand and market acceptance.
Supportive ifSkyrizi revenue growth reported above 20% year over year.
Worry ifSkyrizi revenue growth reported below 15% year over year.
Why it matters: High IPR&D costs can greatly impact AbbVie’s earnings per share.
Worry ifIPR&D and milestones expense impact on EPS reported above $0.50.
Less concerning ifIPR&D and milestones expense impact on EPS reported below $0.30.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$101 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $241 loss on $10,000 · 2.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,731 loss on $10,000 · 17.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.